Paper Details

  1. Home
  2. Paper Details

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

Author: , AllgeierA, BrandesA A, ChinotO, FrenayM, GorliaT, KrosJ M, MentenJ, StuppR, TaphoornM J B, VechtCh J, van den BentM J, van der RijtC C D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Temozolomide is a chemotherapy drug that has been used to treat recurrent anaplastic astrocytoma. This study investigated the use of temozolomide as a first-line chemotherapy for recurrent oligodendroglial tumors and mixed oligoastrocytomas after surgery and radiation therapy.
Paper Details　
Original Abstract of the Article :
Oligodendroglial tumors are chemotherapy-sensitive tumors, with two thirds of patients responding to combination chemotherapy with procarbazine, lomustine, and vincristine (PCV). Temozolomide (TMZ), a new alkylating and methylating agent, has demonstrated high response rates in patients with recurre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12829671

データ提供：米国国立医学図書館（NLM）

Temozolomide: A New Oasis in the Desert of Oligodendroglial Tumor Treatment

This study investigates the effectiveness of temozolomide (TMZ) as a first-line chemotherapy for recurrent oligodendroglial tumors. Oligodendroglial tumors, like sand dunes, are challenging to treat, and this research explores a new approach to combating their recurrence. This study is a clinical trial evaluating the efficacy of TMZ as a first-line chemotherapy for recurrent oligodendroglial tumors and mixed oligoastrocytomas. The researchers meticulously tracked the response rates of patients, providing valuable insights into the potential of TMZ in treating these challenging tumors.

Temozolomide: A Promising Alternative for Recurrent Oligodendroglial Tumors

The study findings suggest that TMZ may be a viable alternative to traditional chemotherapy regimens like PCV for recurrent oligodendroglial tumors. This is like finding a new source of water in the desert – a promising alternative to relying solely on existing sources. The researchers observed high response rates in patients treated with TMZ, suggesting its potential as a first-line chemotherapy option.

A New Path in Oligodendroglial Tumor Treatment

This study highlights the potential of TMZ as a first-line chemotherapy option for recurrent oligodendroglial tumors. This is like discovering a new path through the desert, a path that can lead to better treatment outcomes for patients facing this challenging disease. Further research is needed to determine the optimal use of TMZ in treating these tumors, but this study offers a promising new direction for managing recurrent oligodendroglial tumors.

Dr. Camel's Conclusion

This study offers a valuable contribution to our understanding of oligodendroglial tumor treatment. It’s like finding a new oasis in the desert, providing hope for patients facing the challenges of recurrent tumors. The findings suggest that TMZ could be a valuable tool in the fight against these challenging cancers.

Date :
  1. Date Completed 2003-07-15
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

12829671

DOI: Digital Object Identifier

JCO.2003.12.015

Related Literature

Article Analysis
・Side Effects of lomustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.